U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H24FN3O3
Molecular Weight 373.4213
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CP-615003

SMILES

CCCNCCOC1=C(F)C=C(NC(=O)C2=CNC3=C2C(=O)CCC3)C=C1

InChI

InChIKey=YZHJISPIBWKWGY-UHFFFAOYSA-N
InChI=1S/C20H24FN3O3/c1-2-8-22-9-10-27-18-7-6-13(11-15(18)21)24-20(26)14-12-23-16-4-3-5-17(25)19(14)16/h6-7,11-12,22-23H,2-5,8-10H2,1H3,(H,24,26)

HIDE SMILES / InChI
Molecular Formula C20H24FN3O3
Molecular Weight 373.4213
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.sec.gov/Archives/edgar/data/849043/000084904301500010/0000849043-01-500010.txt | http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=21165 | http://adisinsight.springer.com/drugs/800011480 | https://www.ncbi.nlm.nih.gov/pubmed/12871032

The investigational psychopharmacologic drug candidate CP 615003 (NGD 91-3) is a potent subtype-selective partial agonist at the GABA-A receptor complex. It was designed to be fast acting without causing the sedation, memory impairment, addiction or potentiation of effects of alcohol associated with conventional anti-anxiety medication. Tissue distribution studies conducted during early clinical development of CP 615003 suggested limited brain penetration. In the Phase II clinical study, subjects tested at the high dose of NGD 91-3 showed a trend toward efficacy that did not achieve statistical significance.

CNS Activity

Originator

Neurogen|Pfizer
2
Curator's Comment: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=21171 # Neurogen Corporation; Pfizer

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Partial Agonist
290
 1.1 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
34.6 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17470526/
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CP-900,725 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
173 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17470526/
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CP-615,003 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
277 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17470526/
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CP-900,725 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1052 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/17470526/
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CP-615,003 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 2 times / day steady-state, oral (unknown)
Studied dose
Dose: 100 mg, 2 times / day
Route: oral
Route: steady-state
Dose: 100 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17470526
healthy
n = 6
Health Status: healthy
Sex: M+F
Food Status: UNKNOWN
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/17470526
Sources:
https://pubmed.ncbi.nlm.nih.gov/17470526
Sourcing

Sourcing

Vendor/AggregatorIDURL
Axon MedChem
1604
https://www.axonmedchem.com/product/1604
MolPort
MolPort-042-665-720
https://www.molport.com/shop/molecule-link/MolPort-042-665-720
Toronto Research Chemicals
K384325
https://www.trc-canada.com/product-detail/?CatNum=K384325
eMolecules
36367176
https://orderbb.emolecules.com/search/#?query=36367176
PubMed

PubMed

TitleDatePubMed
Patents

Patents

US20040009214 A1
2
US6964777 B2
2

Sample Use Guides

In Vivo Use Guide
100 mg b.i.d.
Route of Administration: Oral
In Vitro Use Guide
The apparent permeabilities (Papp values) of CP 615003 in the absorptive direction (A to B) across parental MDCK cells were 2,8*10^6 cm/s, indicating at least moderate transcellular permeability.
Substance Class Chemical
Created
by admin
on Sat Dec 16 13:58:10 GMT 2023
Edited
by admin
on Sat Dec 16 13:58:10 GMT 2023
Record UNII
F8CYO0R7I1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CP-615003
Code English
1H-INDOLE-3-CARBOXAMIDE, N-(3-FLUORO-4-(2-(PROPYLAMINO)ETHOXY)PHENYL)-4,5,6,7-TETRAHYDRO-4-OXO-
Systematic Name English
N-(3-FLUORO-4-(2-(PROPYLAMINO)ETHOXY)PHENYL)-4,5,6,7-TETRAHYDRO-4-OXO-1H-INDOLE-3-CARBOXAMIDE
Systematic Name English
Code System Code Type Description
WIKIPEDIA
CP-615,003
Created by admin on Sat Dec 16 13:58:11 GMT 2023 , Edited by admin on Sat Dec 16 13:58:11 GMT 2023
PRIMARY
FDA UNII
F8CYO0R7I1
Created by admin on Sat Dec 16 13:58:11 GMT 2023 , Edited by admin on Sat Dec 16 13:58:11 GMT 2023
PRIMARY
PUBCHEM
9820874
Created by admin on Sat Dec 16 13:58:11 GMT 2023 , Edited by admin on Sat Dec 16 13:58:11 GMT 2023
PRIMARY
EPA CompTox
DTXSID80431338
Created by admin on Sat Dec 16 13:58:11 GMT 2023 , Edited by admin on Sat Dec 16 13:58:11 GMT 2023
PRIMARY
CAS
329016-45-7
Created by admin on Sat Dec 16 13:58:11 GMT 2023 , Edited by admin on Sat Dec 16 13:58:11 GMT 2023
PRIMARY
Related Record Type Details
Structure of CP-615003
EXCRETED UNCHANGED
URINE
Structure of CP-615003
EXCRETED UNCHANGED
FECAL
Structure of CP-615003 MESYLATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of N-(3-FLUORO-4-(2-(2-HYDROXYETHYLAMINO)ETHOXY)PHENYL)-4-OXO-1,5,6,7-TETRAHYDROINDOLE-3-CARBOXAMIDE
METABOLITE -> PARENT
PLASMA
Structure of 2-(2-(2-FLUORO-4-((4-OXO-1,5,6,7-TETRAHYDROINDOLE-3-CARBONYL)AMINO)PHENOXY)ETHYLAMINO)ACETIC ACID
METABOLITE -> PARENT
URINE
Structure of N-(2-(2-FLUORO-4-(((4,5,6,7-TETRAHYDRO-4-OXO-1H-INDOL-3-YL)CARBONYL)AMINO)PHENOXY)ETHYL)-N-PROPYLCARBAMIC ACID
METABOLITE -> PARENT
PLASMA
Structure of 2-(2-(2-FLUORO-4-((4-OXO-1,5,6,7-TETRAHYDROINDOLE-3-CARBONYL)AMINO)PHENOXY)ETHYLAMINO)ACETIC ACID
METABOLITE -> PARENT
FECAL
Structure of 2-(2-(2-FLUORO-4-((4-OXO-1,5,6,7-TETRAHYDROINDOLE-3-CARBONYL)AMINO)PHENOXY)ETHYLAMINO)ACETIC ACID
METABOLITE -> PARENT
PLASMA
Structure of N-(3-FLUORO-4-(2-(2-HYDROXYETHYLAMINO)ETHOXY)PHENYL)-4-OXO-1,5,6,7-TETRAHYDROINDOLE-3-CARBOXAMIDE
METABOLITE -> PARENT
FECAL
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC P.O. ADMINISTRATION

SINGLE DOSE

Tmax PHARMACOKINETIC P.O. ADMINISTRATION

SINGLE DOSE

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966